About ReNewVax

ReNewVax develops pneumococcal vaccines using a proprietary protein-based adjuvanted formulation to prevent life-threatening bacterial infections and combat antimicrobial resistance. Their lead program, RVX-001, aims to be the first universal vaccine for _Streptococcus pneumoniae_, with Phase 1 clinical trials expected to begin by the end of 2025.

```xml <problem> _Streptococcus pneumoniae_ causes life-threatening bacterial infections, and current vaccines do not offer universal protection, contributing to antimicrobial resistance. The development of broad-coverage pneumococcal vaccines is needed to combat the spread of resistant strains and reduce the global burden of pneumococcal disease. </problem> <solution> ReNewVax is developing a novel protein-based adjuvanted vaccine, RVX-001, designed to provide broad protection against _Streptococcus pneumoniae_. This vaccine aims to overcome the limitations of existing pneumococcal vaccines by targeting multiple serotypes and reducing the reliance on antibiotics. By stimulating a robust immune response, RVX-001 has the potential to be a universal pneumococcal vaccine, preventing invasive bacterial infections and mitigating the rise of antimicrobial resistance. The company is also developing rationally-designed vaccines against _Streptococcus agalactiae_ (GBS) and _Streptococcus pyogenes_ (GAS). </solution> <features> - RVX-001: A protein-based adjuvanted vaccine targeting _Streptococcus pneumoniae_ - Broad coverage against multiple pneumococcal serotypes - Designed to induce a strong and durable immune response - Aims to reduce the incidence of pneumococcal infections and antimicrobial resistance - RVX-002: mRNA vaccine in preclinical studies targeting _Streptococcus agalactiae_ (GBS) - RVX-003: Vaccine candidate selection in progress targeting _Streptococcus pyogenes_ (GAS) </features> <target_audience> The primary target audience includes individuals at risk of pneumococcal infections, such as infants, the elderly, and immunocompromised individuals, as well as public health organizations seeking to reduce the burden of pneumococcal disease. </target_audience> ```

What does ReNewVax do?

Where is ReNewVax located?

ReNewVax is based in Liverpool, United Kingdom.

When was ReNewVax founded?

ReNewVax was founded in 2022.

How much funding has ReNewVax raised?

ReNewVax has raised 3960000.

Location

Liverpool, United Kingdom

Founded

2022

Funding

3960000

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

ReNewVax

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

renewvax.com LinkedIn Profile

Founded 2022 – Liverpool, United Kingdom

Funding

Estimated Funding

$3M+

Team

No team information available.

Company Description

Problem

_Streptococcus pneumoniae_ causes life-threatening bacterial infections, and current vaccines do not offer universal protection, contributing to antimicrobial resistance. The development of broad-coverage pneumococcal vaccines is needed to combat the spread of resistant strains and reduce the global burden of pneumococcal disease.

Solution

ReNewVax is developing a novel protein-based adjuvanted vaccine, RVX-001, designed to provide broad protection against _Streptococcus pneumoniae_. This vaccine aims to overcome the limitations of existing pneumococcal vaccines by targeting multiple serotypes and reducing the reliance on antibiotics. By stimulating a robust immune response, RVX-001 has the potential to be a universal pneumococcal vaccine, preventing invasive bacterial infections and mitigating the rise of antimicrobial resistance. The company is also developing rationally-designed vaccines against _Streptococcus agalactiae_ (GBS) and _Streptococcus pyogenes_ (GAS).

Features

RVX-001: A protein-based adjuvanted vaccine targeting _Streptococcus pneumoniae_

Broad coverage against multiple pneumococcal serotypes

Designed to induce a strong and durable immune response

Aims to reduce the incidence of pneumococcal infections and antimicrobial resistance

RVX-002: mRNA vaccine in preclinical studies targeting _Streptococcus agalactiae_ (GBS)

RVX-003: Vaccine candidate selection in progress targeting _Streptococcus pyogenes_ (GAS)

Target Audience

The primary target audience includes individuals at risk of pneumococcal infections, such as infants, the elderly, and immunocompromised individuals, as well as public health organizations seeking to reduce the burden of pneumococcal disease.